Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 24

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Effect of testosterone treatment on bone remodelling markers and mineral density in obese dieting men in a randomized clinical trial

Ng Tang Fui, Mark, Hoermann, Rudolf, Nolan, Brendan, Clarke, Michelle, Zajac, Jeffrey D., Grossmann, Mathis·2018·Scientific Reports
DOI 10.1038/s41598-018-27481-3
Open this paper in CoChat — free account

Abstract

To assess the effect of testosterone treatment on bone remodelling and density in dieting obese men, 100 obese men aged 53 years (interquartile range 47–60) with a total testosterone level <12 nmol/L receiving 10 weeks of a very low energy diet (VLED) followed by 46 weeks of weight maintenance were randomly assigned at baseline to 56 weeks of intramuscular testosterone undecanoate (n = 49, cases) or matching placebo (n = 51, controls). Pre-specified outcomes were between-group differences (mean adjusted difference, MAD) in serum c-telopeptide (CTx), N-terminal propeptide of type 1 procollagen (P1NP) and bone mineral density (BMD). At trial end, CTx was significantly reduced in men receiving testosterone compared to placebo, MAD −66 ng/L (95% CI −113, −18), p = 0.018, and this was apparent already after the 10 week VLED phase, MAD −63 ng/L (95% CI −108, −18), p = 0.018. P1NP was marginally increased after VLED, MAD +4.2 ug/L (95% CI −0.01, +8.4), p = 0.05 but lower at study end, MAD −5.6 ug/L (95% CI −10.1, −1.1), p = 0.03. No significant changes in sclerostin, lumbar spine BMD or femoral BMD were seen. We conclude that in obese men with low testosterone levels undergoing weight loss, bone remodelling markers are modulated in a way that may have favourable effects on bone mass.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-018-27481-3

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 21

  1. Sogaard, A. J. et al. Abdominal obesity increases the risk of hip fracture. A population-based study of 43,000 women and men aged 60–79 years followed for 8 years. J. Int. Med. 277, 306–317 (2015). · DOI
  2. Khosla, S. et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J. Clin. Endocrinol. Metab. 83, 2266–2274 (1998).
  3. Barrett-Connor, E. et al. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J. Clin. Endocrinol. Metab. 85, 219–223 (2000).
  4. Scott, D. et al. Sarcopenic obesity and its temporal associations with changes in bone mineral density, incident falls, and fractures in older men: The Concord Health and Ageing in Men Project. J. Bone Miner. Res. 32, 575–583 (2017). · DOI
  5. Schwartz, A. V. et al. Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial. J. Bone Miner. Res. 27, 619–627 (2012). · DOI
  6. Schafer, A. L. Decline in Bone Mass During Weight Loss: A Cause for Concern? J. Bone Miner. Res. 31, 36–39 (2016). · DOI
  7. Amory, J. K. et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 89, 503–510 (2004). · DOI · Paper page
  8. Manolagas, S. C., O’Brien, C. A. & Almeida, M. The role of estrogen and androgen receptors in bone health and disease. Nat. Rev. Endocrinol. 9, 699–712 (2013). · DOI
  9. Bhasin, S. et al. Drug insight: testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat. Clin. Pract. Endocrinol. Metab. 2, 146–159 (2006). · DOI · Paper page
  10. Harwood, D. T. & Handelsman, D. J. Development and validation of a sensitive liquid chromatography-tandem mass spectrometry assay to simultaneously measure androgens and estrogens in serum without derivatization. Clin. Chim. Acta 409, 78–84 (2009). · DOI
  11. Vermeulen, A., Verdonck, L. & Kaufman, J. M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J. Clin. Endocrinol. Metab. 84, 3666–3672 (1999). · DOI · Paper page
  12. Bates, K., Machler, M., Bolker, B. M. & Walker, S. C. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67, 1–48 (2015). · DOI · Paper page
  13. Wang, C. et al. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men. Clin. Endocrinol. (Ox.f) 54, 739–750 (2001). · DOI
  14. Di Nisio, A. et al. Regulation of sclerostin production in human male osteocytes by androgens: experimental and clinical rvidence. Endocrinology 156, 4534–4544 (2015). · DOI
  15. Modder, U. I. et al. Regulation of circulating sclerostin levels by sex steroids in women and in men. J. Bone Miner. Res. 26, 27–34 (2011). · DOI · Paper page
  16. Dimitri, P. & Rosen, C. The central nervous system and bone metabolism: an evolving story. Calcif. Tissue Int. 100, 476–485 (2017). · DOI
  17. Prouteau, S., Benhamou, L. & Courteix, D. Relationships between serum leptin and bone markers during stable weight, weight reduction and weight regain in male and female judoists. Eur. J. Endocrinol. 154, 389–395 (2006). · DOI
  18. Fui, N. T., Hoermann, M. & Grossmann, R. M. Effect of testosterone treatment on adipokines and gut hormones in obese men on a hypocaloric diet. J. Endo. Soc. 1, 302–312 (2017). · DOI
  19. Jockenhovel, F. et al. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J. Clin. Endocrinol. Metab. 82, 2510–2513 (1997). · DOI · Paper page
  20. Kenny, A. M., Prestwood, K. M., Gruman, C. A., Marcello, K. M. & Raisz, L. G. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J. Gerontol. A. Biol. Sci. Med. Sci. 56, M266–M272 (2001). · DOI · Paper page
  21. Kenny, A. M. et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J. Am. Geriatr. Soc. 58, 1134–1143 (2010). · DOI · Paper page

Cited by

Metadata

Authors
Ng Tang Fui, M., Hoermann, R., Nolan, B., Clarke, M., Zajac, J. D., & Grossmann, M.
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2018-06-14
Volume
8
Issue
1
ISSN
2045-2322
DOI
10.1038/s41598-018-27481-3
Cited by
24
References
15
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.